Andy Chen
Stock Analyst at Wolfe Research
(3.25)
# 864
Out of 5,150 analysts
43
Total ratings
53.85%
Success rate
15.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $72.31 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $27.08 | +84.64% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $86.11 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $477.89 | +14.67% | 2 | Jan 6, 2026 | |
| ARGX argenx SE | Downgrades: Peer Perform | n/a | $749.56 | - | 3 | Nov 24, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Peer Perform | n/a | $13.82 | - | 3 | Nov 12, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $19.86 | - | 1 | Nov 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $327.30 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $39.65 | - | 2 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $66.54 | -26.36% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $16.09 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $61 | $18.14 | +236.27% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $60.55 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $39.51 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $34.99 | -42.84% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $25.82 | -26.41% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $98.86 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $29.54 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $434.80 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $30.39 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $58.01 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $79.45 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $60.00 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $29.52 | -42.41% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $149.88 | -71.98% | 1 | Feb 15, 2024 |
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $72.31
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $27.08
Upside: +84.64%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $86.11
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $477.89
Upside: +14.67%
argenx SE
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $749.56
Upside: -
Intellia Therapeutics
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $13.82
Upside: -
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $19.86
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $327.30
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $39.65
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $66.54
Upside: -26.36%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $16.09
Upside: -
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $18.14
Upside: +236.27%
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $60.55
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $39.51
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $34.99
Upside: -42.84%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $25.82
Upside: -26.41%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $98.86
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $29.54
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $434.80
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $30.39
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $58.01
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $79.45
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $60.00
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $29.52
Upside: -42.41%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $149.88
Upside: -71.98%